Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing

Author(s)
Yasukawa, Shinichiro; Kano, Satoshi; Hatakeyama, Hiromitsu; Nakamaru, Yuji; Takagi, Dai; Mizumachi, Takatsugu; Suzuki, Masanobu; Suzuki, Takayoshi; Nakazono, Akira; Tanaka, Shinya; Nishihara, Hiroshi; Homma, Akihiro

Citation
International journal of clinical oncology, 23(5), 835-843
https://doi.org/10.1007/s10147-018-1296-1

Issue Date
2018-10

Doc URL
http://hdl.handle.net/2115/74188

Rights
This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-1296-1

Type
article (author version)

File Information
IJCO23_835.pdf
Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing

Shinichiro Yasukawa, M.D.¹, Satoshi Kano, M.D., Ph.D.¹, Hiromitsu Hatakeyama, M.D., Ph.D.², Yuji Nakamaru, M.D., Ph.D.¹, Dai Takagi, M.D., Ph.D.¹, Takatsugu Mizumachi, M.D., Ph.D.¹, Masanobu Suzuki, M.D., Ph.D.¹, Takayoshi Suzuki, M.D.¹, Akira Nakazono, M.D.¹, Shinya Tanaka, M.D., Ph.D.³, Hiroshi Nishihara, M.D., Ph.D.⁴, Akihiro Homma, M.D., Ph.D.¹

¹ Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

² Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.

³ Department of Cancer Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

⁴ Department of Cancer Center, Keio University Hospital, Tokyo, Japan.
Corresponding author: Satoshi Kano, Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060·8638, Japan,
Tel: +81·11·706·5958, Fax: +81·11·717·7566,
E-mail: skano@med.hokudai.ac.jp
Abstract

Background. The mechanism underlying the malignant transformation of inverted papilloma (IP) has not yet been elucidated.

Methods. To clarify the genes responsible for the malignant transformation, we analyzed 10 cases of IP, 8 of IP with dysplasia, and 11 of squamous cell carcinoma (SCC) by targeted amplicon sequencing.

Results. The number of mutant genes increased in the order of IP<dysplasia<SCC. Significant differences were observed in the mutation rates of 3 genes (KRAS, APC and STK11) in particular. TP53 was altered frequently in each group and might be involved in malignant transformation based on the site of the mutation. A comparison of the genetic variants by region of IP tissue among patients with IP alone, and those with dysplasia or SCC revealed significant differences in the mutation rate of the KRAS gene.

Conclusion. Identification of genetic mutations in KRAS is effective for predicting the malignant transformation of IP.

Keywords: inverted papilloma, malignant transformation, squamous cell carcinoma, targeted amplicon sequence, NGS
Introduction

Sinonasal papilloma accounts for 0.4-4.7% of all nasal tumors and is histopathologically classified into three types: inverted papilloma (IP), exophytic papilloma and oncocytic papilloma.\(^1\) IP represents the most commonly diagnosed subtype of sinonasal papilloma with an incidence of 0.74-1.5 cases per 100,000 inhabitants per year.\(^2\) IP is pathologically regarded as a benign tumor, but its malignant transformation is known to occur at a rate of 3.8-10%.\(^3-6\) Therefore, the standard treatment for IP is complete resection. However, it is impossible to completely diagnose the malignant transformation of IP by macroscopic findings and computed tomography (CT) or magnetic response imaging (MRI) before surgical resection. Most of the malignant tissues present as squamous cell carcinoma (SCC). SCC within IP has been reported to occupy 10 to 95% of the total tumor volume.\(^7\) Therefore, a preoperative biopsy may not include areas of the IP showing malignant change and, therefore, is not always effective in assisting the clinician in reaching a correct diagnosis. Therefore, multiple preoperative biopsies from different sites within the tumor tissue may be necessary to prevent misdiagnosis.
Recently, next-generation sequencer (NGS) has been widely used at the forefront of research, affording considerable progress in the identification of the responsible genes in several diseases. The clinical applications of whole genome sequencing and whole exosome sequencing were limited in terms of the cost and time required; however, it has recently become possible to efficiently retrieve the target genes by amplicon sequencing. These technological innovations mean that NGS can now be clinically applied for some types of tumors, including head and neck tumors.

Although many investigations into the etiology and behavior of IP have been undertaken, the exact mechanism of its malignant transformation has not yet been fully elucidated. To clarify the genetic variants involved in the malignant transformation of IP, we analyzed the genetic variants in the tissues associated with IP, dysplasia and SCC by target amplicon sequencing with NGS and compared the differences in variants between the tissues. If the genes responsible for the malignant transformation of IP can be identified, it will become possible to predict malignant change in IP through examining alterations in those genes.
Materials and methods

Patient selection and histologic review

We selected 29 patients with IP or SCC involving the nasal or paranasal sinus who were treated at Hokkaido University Hospital between 2007 and 2015. Of the 29 patients, 10 had IP alone, 8 had IP with dysplasia, and 11 had SCC (Figure 1). Of the 11 cases with SCC, 5 had coexisting IP. In cases in which IP coexisted with dysplasia or SCC, the region of each different tissue was evaluated separately. Patients consisted of 21 males and 8 females, with a median age of 64 years (range 44-79 years). All hematoxylin & eosin-stained specimens were reviewed, and histopathological type was confirmed by 2 expert pathologists (S.T. and H.N.). This study was approved by the Ethics Committee of the Hokkaido University Hospital Clinical Research management unit, and informed consent was obtained from each patient.

DNA extraction

Formalin-fixed paraffin-embedded (FFPE) tissue samples were cut into 10 μm slices to create 5 specimens, and then genomic DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, NRW, Germany). The concentration of the genomic DNA was measured by Qubit dsDNA BR Assay
Kit (Invitrogen, Carlsbad, CA, USA) and GeneRead DNA QuantiMIXE Assay Kit (Qiagen).

**Target amplicon sequencing**

We used TruSight Tumor 26 (Illumina, San Diego, CA, USA) as an amplicon sequence panel. This panel can sequence 175 amplicon regions of 26 genes that are closely related to solid tumors of the lung, colon, melanoma, stomach, and ovary: **AKT1, EGFR, GNAS, NRAS, STK11, ALK, ERBB2, KIT, PDGFRA, TP53, APC, FBXW7, KRAS, PIK3CA, BRAF, GFR2, MAP2K1, PTEN, CDH1, FOXL2, MET, SMAD4, CTNNB1, GNAQ, MSH6, and SRC.**

**Creation of a DNA library**

Using the obtained genomic DNA, we then amplified the target genes by a polymerase chain reaction (PCR) method with Gene Read DNA seq Panel PCR Regent V2 (Qiagen). To collect the amplified DNA, the PCR products were added to Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA), bound to magnetic beads, and then eluted from the magnetic beads. Terminal repair and adapter ligation were performed using a Gene Read DNA Library Core Kit (Qiagen) to prepare a purified DNA library. The DNA library was amplified by PCR with a GeneRead DNA Amp Kit (Qiagen), and purified
using a MinElute PCR Purification Kit (Qiagen). The amplified DNA library was sequenced by Miseq (Illumina).

Data analysis

The FastQ file obtained from Miseq by target amplicon sequencing was analyzed using the BaseSpace Variant Studio Ver 2.2 analysis server provided by Illumina. We detected single nucleotide polymorphisms (SNPs) with a base insertion and deletion. The SNPs were limited to mutations causing amino acid substitutions with a positive mutation rate of more than 10%.

Statistical analysis

For statistical analysis, Excel statistics version 1.03 (Social Information Service, Tokyo, Tokyo, Japan) was used. Kruskal-Wallis test was used to compare the number of mutant genes among the 3 groups, and chi-square test was used to compare the mutation rate of each gene. A p value of less than 0.05 was judged to be statistically significant.

Results

Correlations between genetic variants and histological type

We could detect one or more genetic mutations in each of the 29 cases, with a
total of 129 mutations with amino acid substitutions detected. In the 26 genes analyzed using the sequence panel, the average number of mutant genes was 2.9 (range 1-5) in the IP tissue from patients with IP alone, 4.4 (range 3-6) in the dysplastic tissue from patients with IP with dysplasia, and 5.7 (range 3-9) in the carcinoma tissue from patients with SCC with or without IP (Figure 2). The number of mutant genes increased in the order of IP < dysplasia < SCC, and there was a significant difference in the number of mutated genes between the IP and SCC tissue ($P = 0.042$, Figure 3). When dysplasia was divided into two groups based on the grading of dysplasia, the average number of mutant genes was 4.7 (range 3-6) in the low-grade dysplastic tissues (case number 11, 12, 13, 14, 17 and 18) and 3.5 (range 3-4) in the high-grade dysplastic tissues (case number 15 and 16). There was no significant difference between the two groups in terms of the number or pattern of mutant genes. When SCC was further divided into two groups, the average number of mutant genes was 5.6 (range 4-7) in the carcinoma tissue from patients with SCC with IP and 5.8 (range 3-9) in the carcinoma tissue from patients with SCC without IP, which we regarded as de novo SCC. There was no significant difference between the two groups in terms of the number or
pattern of mutant genes.

Analysis of each gene revealed significant differences in the mutation rates of the following 3 genes among the IP, dysplasia and SCC groups (Table 1). \textit{KRAS} and \textit{APC} were found to be altered less frequently in the IP group (10 and 0%), while they were more frequently mutated in the dysplasia (75 and 50%) and SCC (73 and 64%) groups. No alterations in \textit{STK11} were found in the IP and dysplasia groups, while it was more frequently mutated in the SCC group (36%). \textit{TP53} was found to be altered frequently in each group (IP, 70%; dysplasia, 75%; SCC, 91%), with no significant differences observed among the three groups.

**Variants detected multiple times across all patients**

Table 2 shows the position on the chromosome and frequency of genetic variants detected multiple times across the 29 patients. Relatively frequent alterations were observed for \textit{TP53}, g.7579472G>C (26%; overall, IP, 30%; dysplasia, 25%; SCC, 27%) and \textit{APC}, g.112175770G>A (24%; overall, IP, 0%; dysplasia, 25%; SCC, 27%).

**Differences in genetic variants in the same patient**

We compared the differences in genetic variants between the regions of IP
and dysplastic tissue in the same patient with IP with coexistent dysplasia. A total 39 mutant genes were found in either the IP or dysplastic tissue in 8 cases, while 4 mutant genes (10%) were found in the IP alone, and 6 mutant genes (15%) in the dysplastic tissue alone (Figure 4). Similarly, we compared the differences in genetic variants between the IP and SCC regions in the same patient with IP with coexistent SCC. A total 29 mutant genes were found in either the IP or SCC tissue in 5 cases, while 1 mutant gene (3%) was found in the IP alone, and 2 mutant genes (7%) in the SCC tissue alone (Figure 5). In both IP with dysplasia and IP with SCC, little difference was observed in the genetic variants between the IP tissue and coexisting dysplasia or SCC tissue.

**Genetic variants in the IP tissue among patients with IP alone, IP with dysplasia and IP with SCC**

Furthermore, we compared genetic variants in the IP tissue among patients with IP alone, IP with dysplasia and IP with SCC (Figure 6). The number of mutant genes increased in the order of IP<IP with dysplasia<IP with SCC, and there was a significant difference in the number of mutated genes in the IP tissue between patients with IP alone and those with IP with SCC ($P =$
0.030, Figure 7). The analysis of each gene revealed that there was significant difference in the genetic mutation of *KRA* in the IP tissue between patients with IP and those with IP with dysplasia/SCC (*P* = 0.005, Table 3). Therefore, we calculated the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for patients with coexistent dysplasia or SCC. Results showed that the sensitivity of the detection of dysplasia or SCC using the *KRA* mutation was 85%, the specificity was 90%, the PPV was 91% and the NPV was 75%.

**Discussion**

Recently, several investigators have reported on candidate biomarkers for the malignant transformation of sinonasal IP. Cyclooxygenase-2, which is induced by mitogenic and inflammatory stimuli and promotes tumorigenesis, has been reported to be overexpressed significantly in IP with SCC compared to the level observed in benign IP. Human papilloma virus (HPV) shows higher viral loads in patients with IP/SCC than in those with IP. A recent systemic review with meta-analysis found a statistically significant association between HPV infection and malignant transformation of IP.
Furthermore, proapoptotic factors such as p53, p21, p16, p27, tissue factor pathway inhibitor-2, p63, bcl-2 family, Ki-67, proliferating cell nuclear antigen and intercellular adhesion molecules have all been evaluated as possible contributors to IP malignant transformation.\textsuperscript{14-19} However, there have been few reports on genetic variants associated with the malignant transformation of IP to date. Udager et al. reported that EGFR mutations were found in 88\% of patients with IP and 77\% of those with IP with SCC, but this difference was not significant.\textsuperscript{20}

Therefore, we undertook a comprehensive analysis of genetic alterations in 26 genes closely related to solid tumors by target amplicon sequencing with NGS. As a result, the number of mutant genes was found to increase in the order of IP\textless dysplasia\textless SCC (Figure 3). In particular, there were significant differences in the mutation rates of 3 genes: \textit{KRAS}, \textit{APC}, and \textit{STK11} (Table 1). Furthermore, there was a significant difference in the genetic mutation of \textit{KRAS} in the IP tissue between patients with IP alone and those with IP with dysplasia/SCC (Table 3). This finding strongly suggested that \textit{KRAS} mutations could be involved in the malignant transformation of IP. Regarding the genetic alterations in \textit{KRAS}, Udager et al. reported that
KRAS mutations were identified in all cases with oncocytic papilloma, a subtype of sinonasal papilloma, and oncocytic papilloma-associated SCC. However, they also reported that there were no KRAS mutations in either IP or IP-associated SCC.

On the other hand, TP53 was found to be altered frequently in all groups (IP, 70%; dysplasia, 75%; SCC, 91%), but there were no significant differences among the three groups in this study (Table 1). However, in the analysis of gene mutation site, the g. 7570312C>A mutation was detected in 7% of all cases, with all cases limited to the SCC group (18%). In addition, the g. 7577150T>A mutation was detected in 10% of all cases, with all cases found in patients with either dysplasia or SCC (13% and 18%, respectively) (Table 2). Lin et al. showed that tissue from IP with carcinoma is positively stained for p53 at more than twice the frequency than that observed in tissue from IP alone based on an immunohistochemical approach (62% versus 30%), and suggested that alterations in p53 are important in the progression of IP to malignant disease. These results suggest that p53 protein dysfunction, dependent on the site of the TP53 mutation, could be involved in the malignant transformation of IP.
Currently, the diagnosis of SCC derived from IP requires the pathological existence of IP. However, if the IP is completely replaced by carcinoma, or if carcinoma alone occurs after complete IP resection, a differential diagnosis between SCC derived from IP and de novo SCC would be impossible. However, if the IP and SCC occur independently and the SCC invades the nearby IP, de novo SCC might be misdiagnosed as SCC derived from IP. In this study, we compared genetic variants between SCC with IP and de novo SCC, and no significant differences were observed between the two groups in terms of the number and pattern of mutant genes. Therefore, this study indicated that a differential diagnosis between SCC derived from IP and de novo SCC is impossible based on genetic alterations.

As IP occasionally progresses to malignant transformation, its standard treatment is complete resection. The nasal and paranasal sinuses, where IP arises, are anatomically adjacent to important organs such as the orbit and skull base; therefore, extended surgery for carcinoma derived from papilloma could have a great influence on postoperative complications and dysfunction. Accordingly, if we can predict the incidence of carcinoma within IP tissue prior to surgery, we could set an appropriate resection line and avoid
unnecessarily extensive surgery. However, it is currently impossible to completely diagnose the malignant transformation of IP by macroscopic findings and CT or MRI before surgical resection. Furthermore, even if a preoperative biopsy is performed, carcinoma tissue might not be contained in the biopsied specimen. Therefore, it would be clinically very beneficial to develop a new preoperative method for the diagnosis of the malignant transformation of IP.

We examined the differences in genetic variants between the IP and dysplasia or SCC tissues in the same patient. As a result, a total of 39 mutant genes were found in either the IP or dysplastic tissue, while 4 mutant genes (10%) were found in the IP tissues alone and 6 mutant genes (15%) were found in the dysplastic tissue alone (Figure 4). Similarly, a total of 29 mutant genes were found in either the IP or SCC tissue, while 1 mutant gene (3%) was found in the IP tissue alone and 2 mutant genes (7%) were found in the SCC tissue alone (Figure 5). Accordingly, there was little difference in the genetic variants between IP and the coexisting dysplasia or SCC. These results indicated that it might be possible to predict genetic variants in carcinoma within IP by genetic mutation analysis of the biopsied IP tissue.
Furthermore, we compared genetic variants in the IP tissue among patients with IP alone, IP with dysplasia and IP with SCC. As a result, significant differences were observed in the mutation rates of the \textit{KRAS} gene in the IP tissue between patients with IP and those with IP with dysplasia/SCC (Table 3). Regarding other genes, no genetic mutations of \textit{APC}, \textit{NRAS} and \textit{STK11} were found in patients with IP alone, while such mutations were frequently found in the IP tissue from patients with coexistent dysplasia or SCC. These results suggested that genetic variants of \textit{KRAS}, \textit{APC}, \textit{NRAS} and \textit{STK11} in preoperative biopsy tissue could be predictive of the existence of carcinoma within the IP tissues and the risk of future malignant transformation. If we can predict the existence of carcinoma within IP tissue prior to surgery, it may be possible to select the following treatment strategy: minimally invasive endoscopic sinus surgery for IP with low risk of malignant transformation, while external approach or advanced endoscopic sinus surgery including the bone resection of orbit or skull base for IP with high risk of malignant transformation.

One limitation to this study is that only a limited number of cases were analyzed; therefore, it is necessary to pursue further analysis of a
greater number of cases. Further research will allow for the identification of mutant gene combinations and their mutation sites that can predict malignant transformation of IP more accurately and efficiently.

In conclusion, the results of this study suggested that genetic variants of *KRAS, APC* and *STK11* are involved in the malignant transformation of IP, and *KRAS*, in particular, is the key gene in predicting the malignant transformation of IP.
Conflict of Interest

No author has any conflict of interest.
References

1. Batsakis JG, Suarez P. (2001) Schneiderian papillomas and carcinomas: a review. Adv Anat Pathol 8:53-64

2. Buchwald C, Franzmann MB, Tos M. (1995) Sinonasal papillomas: a report of 82 cases in Copenhagen County, including a longitudinal epidemiological and clinical study. Laryngoscope 105:72-79

3. Re M, Zizzi A, Ferrante L, et al. (2014) p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival. Eur Arch Otorhinolaryngol 271:1641-1651

4. Lawson W, Kaufman MR, Biller HF. (2003) Treatment outcomes in the management of inverted papilloma: an analysis of 160 cases. Laryngoscope 113:1548-1556

5. Schlosser RJ, Mason JC, Gross CW. (2001) Aggressive endoscopic resection of inverted papilloma: an update. Otolaryngol Head Neck Surg 25:49-53

6. Sanderson RJ, Knegt PK. (1999) Management of inverted papilloma via Denker's approach. Clin Otolaryngol 24:69-71

7. Deitmer T, Wiener C. (1996) Is there an occupational etiology of inverted
papilloma of the nose and sinuses? Acta Otolaryngol 116:762-765

8. Davey JW, Hohenlohe PA, Etter PD, et al. (2011) Genome-wide genetic marker discovery and genotyping using next-generation sequencing. Nat Rev Genet 12:499-510

9. Coco S, Truini A, Vanni I, et al. (2015) Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Curr Drug Targets 16:47-59

10. The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576-582

11. Lee GH, Yoon YH, Kim YM, et al. (2012) Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma. Am J Otolaryngol 33(5):585-589

12. Yamashita Y, Hasegawa M, Deng Z, et al. (2015) Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16(INK4a) in sinonasal diseases. Infect Agent Cancer 10:23

13. Zhao RW, Guo ZQ, Zhang RX. (2016) Human papillomavirus infection and the malignant transformation of sinonasal inverted papilloma: A meta-
analysis. J Clin Virol 79:36-43

14. Huang CC, Lee TJ, Chang PH, et al. (2010) Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity. Laryngoscope 120:26-29

15. Koo BS, Jung BJ, Kim SG, et al. (2011) Altered expression of E-cadherin and β-catenin in malignant transformation of sinonasal inverted papillomas. Rhinology 49:479-485

16. Lin GC, Scheel A, Akkina S, et al. (2013) Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma. Int Forum Allergy Rhinol 3:885-889

17. Oncel S, Cosgul T, Calli A, et al. (2011) Evaluation of p53, p63, p21, p27, ki-67 in paranasal sinus squamous cell carcinoma and inverted papilloma. Indian J Otolaryngol Head Neck Surg 63:172-177

18. Tsou YA, Huang HJ, Wang TC, et al. (2014) Evaluation of correlation of cell cycle proteins and Ki-67 interaction in paranasal sinus inverted papilloma prognosis and squamous cell carcinoma transformation. Biomed Res Int 2014:634945

19. Wu HH, Zafar S, Huan Y, et al. (2009) Fascin over expression is associated
with dysplastic changes in sinonasal inverted papillomas: a study of 47 cases. Head Neck Pathol 3:212-216

20. Udager AM, Rolland DCM, McHugh JB, et al. (2015) High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. Cancer Res 75:2600-2606

21. Udager AM, McHugh JB, Betz BL, et al. (2016) Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. J Pathol 239:394-398
**Figure legends**

**Figure 1. Histopathology of inverted papilloma, dysplasia and squamous cell carcinoma**

(A) inverted papilloma (IP), (B) dysplasia with IP, (C) squamous cell carcinoma.

**Figure 2. Mapping of genetic variants among patients with inverted papilloma, dysplasia and squamous cell carcinoma**

Genetic variants were compared among patients with inverted papilloma (IP), dysplasia and squamous cell carcinoma (SCC). SCC was subdivided into SCC with IP and de novo SCC. Black: single nucleotide polymorphism, dark gray: insertion of nucleotide, light gray: deletion of nucleotide.

**Figure 3. Mutated genes among patients with inverted papilloma, dysplasia and squamous cell carcinoma**

A number of mutant genes among patients with inverted papilloma (IP), dysplasia and squamous cell carcinoma (SCC) were compared using Kruskal-Wallis test.
**Figure 4. Mapping of genetic variants in inverted papilloma with dysplastic tissue**

Genetic variants were compared between the inverted papilloma (IP) tissue and dysplastic tissue (Dys) in the same patient with IP with dysplasia. Black: single nucleotide polymorphism, dark gray: insertion of nucleotide, light gray: deletion of nucleotide.

**Figure 5. Mapping of genetic variants in inverted papilloma with squamous cell carcinoma tissue**

Genetic variants were compared between the inverted papilloma (IP) tissue and squamous cell carcinoma (SCC) tissue in the same patient with IP with SCC. Black: single nucleotide polymorphism, dark gray: insertion of nucleotide, light gray: deletion of nucleotide.

**Figure 6. Mapping of genetic variants in the inverted papilloma tissue among patients with inverted papilloma alone, and those with dysplasia or squamous cell carcinoma**
Genetic variants in the inverted papilloma (IP) tissue were compared among patients with IP alone, IP with dysplasia and IP with squamous cell carcinoma. Black: single nucleotide polymorphism, dark gray: insertion of nucleotide, light gray: deletion of nucleotide.

Figure 7. Mutated genes in the inverted papilloma tissue among patients with inverted papilloma alone, and those with dysplasia or squamous cell carcinoma

A number of mutated genes in the inverted papilloma tissue among patients with inverted papilloma (IP) alone, and those with dysplasia or squamous cell carcinoma (SCC) were compared using Kruskal-Wallis test.
Figure 2

| Gene                | Case number  | IP   | Dysplasia | SCC with IP | de novo SCC |
|---------------------|--------------|------|-----------|-------------|-------------|
|                     | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |      |           |             |             |
| TP53                |              |      |           |             |             |
| GNAQ                |              |      |           |             |             |
| PDGFRA              |              |      |           |             |             |
| EGFR                |              |      |           |             |             |
| PIK3CA              |              |      |           |             |             |
| KRAS                |              |      |           |             |             |
| APC                 |              |      |           |             |             |
| NRAS                |              |      |           |             |             |
| STK11               |              |      |           |             |             |
| KIT                 |              |      |           |             |             |
| MSH6                |              |      |           |             |             |
| MET                 |              |      |           |             |             |
| FGFR2               |              |      |           |             |             |
| SRC                 |              |      |           |             |             |
| AKT1                |              |      |           |             |             |
| GNAS                |              |      |           |             |             |
| ALK                 |              |      |           |             |             |
| FBXW7               |              |      |           |             |             |
| PTEN                |              |      |           |             |             |
| CDH1                |              |      |           |             |             |
| FOXL2               |              |      |           |             |             |
| CTNNB1              |              |      |           |             |             |
| ERBB2               |              |      |           |             |             |
| BRAF                |              |      |           |             |             |
| SMAD4               |              |      |           |             |             |
| MAP2K1              |              |      |           |             |             |
| a number of mutations | 4 4 2 4 1 3 2 5 3 1 | 5 6 4 5 3 4 3 5 | 6 6 5 7 4 | 9 8 5 6 3 | 5 |

The table represents the occurrence of mutations in different cases of dysplasia, SCC with IP, and de novo SCC. Each gene is listed on the left, and cases are listed in the rows. The presence of mutations is indicated by shading.
Figure 3

Number of mutated genes

IP (n=10)  Dysplasia (n=8)  SCC (n=11)

$P = 0.042$
| Case number | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|-------------|----|----|----|----|----|----|----|----|
| Region      | IP | Dys | IP | Dys | IP | Dys | IP | Dys |
| TP53        | IP | IP | IP | IP | IP | IP | IP | IP |
| GNAQ        | IP | IP | IP | IP | IP | IP | IP | IP |
| PDGFRA      | IP | IP | IP | IP | IP | IP | IP | IP |
| EGFR        | IP | IP | IP | IP | IP | IP | IP | IP |
| PIK3CA      | IP | IP | IP | IP | IP | IP | IP | IP |
| KRAS        | IP | IP | IP | IP | IP | IP | IP | IP |
| APC         | IP | IP | IP | IP | IP | IP | IP | IP |
| NRAS        | IP | IP | IP | IP | IP | IP | IP | IP |
| STK11       | IP | IP | IP | IP | IP | IP | IP | IP |
| KIT         | IP | IP | IP | IP | IP | IP | IP | IP |
| MSH6        | IP | IP | IP | IP | IP | IP | IP | IP |
| MET         | IP | IP | IP | IP | IP | IP | IP | IP |
| FGFR2       | IP | IP | IP | IP | IP | IP | IP | IP |
| SRC         | IP | IP | IP | IP | IP | IP | IP | IP |
| AKT1        | IP | IP | IP | IP | IP | IP | IP | IP |
| GNAS        | IP | IP | IP | IP | IP | IP | IP | IP |
| ALK         | IP | IP | IP | IP | IP | IP | IP | IP |
| FBXW7       | IP | IP | IP | IP | IP | IP | IP | IP |
| PTEN        | IP | IP | IP | IP | IP | IP | IP | IP |
| CDH1        | IP | IP | IP | IP | IP | IP | IP | IP |
| FOXL2       | IP | IP | IP | IP | IP | IP | IP | IP |
| CTNNB1      | IP | IP | IP | IP | IP | IP | IP | IP |
| ERBB2       | IP | IP | IP | IP | IP | IP | IP | IP |
| BRAF        | IP | IP | IP | IP | IP | IP | IP | IP |
| SMAD4       | IP | IP | IP | IP | IP | IP | IP | IP |
| MAP2K1      | IP | IP | IP | IP | IP | IP | IP | IP |
| a number of mutations | 5 | 5 | 6 | 6 | 2 | 4 | 5 | 5 |
|             | 5 | 5 | 2 | 3 | 6 | 4 | 2 | 3 |
|             | 5 | 5 | 2 | 3 | 6 | 4 | 2 | 3 |

Figure 4
| Gene   | IP with SCC | Case number |
|--------|-------------|-------------|
|        | 19 | 20 | 21 | 22 | 23 |
| Region | IP SCC | IP SCC | IP SCC | IP SCC | IP SCC |
| TP53   |     |     |     |     |     |
| GNAQ   |     |     |     |     |     |
| PDGFRA |     |     |     |     |     |
| EGFR   |     |     |     |     |     |
| PIK3CA |     |     |     |     |     |
| KRAS   |     |     |     |     |     |
| APC    |     |     |     |     |     |
| NRAS   |     |     |     |     |     |
| STK11  |     |     |     |     |     |
| KIT    |     |     |     |     |     |
| MSH6   |     |     |     |     |     |
| MET    |     |     |     |     |     |
| FGFR2  |     |     |     |     |     |
| SRC    |     |     |     |     |     |
| AKT1   |     |     |     |     |     |
| GNAS   |     |     |     |     |     |
| ALK    |     |     |     |     |     |
| FAXW7  |     |     |     |     |     |
| PTEN   |     |     |     |     |     |
| CDH1   |     |     |     |     |     |
| FOXL2  |     |     |     |     |     |
| CTNNB1 |     |     |     |     |     |
| ERBB2  |     |     |     |     |     |
| BRAF   |     |     |     |     |     |
| SMAD4  |     |     |     |     |     |
| MAP2K1 |     |     |     |     |     |
| a number of mutations | 5 | 6 | 5 | 6 | 4 | 5 | 8 | 7 | 4 | 4 |
| Gene       | IP  | IP with dysplasia | IP with SCC |
|------------|-----|-------------------|-------------|
| Case number| 1   | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| TP53       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| GNAQ       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| PDGFRA     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| EGFR       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| PIK3CA     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| KRAS       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| APC        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| NRAS       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| STK11      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| KIT        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| MSH6       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| MET        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| FGFR2      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| SRC        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| AKT1       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| GNAS       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| ALK        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| FBXW7      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| PTEN       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| CDH1       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| FOXL2      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| CTNNB1     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| ERBB2      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| BRAF       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| SMAD4      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| MAP2K1     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

a number of mutations: 4 4 2 4 1 3 2 5 3 1 5 6 2 5 2 6 2 5 5 5 4 8 4
Figure 7

Number of mutated genes

IP (n=10)  IP with dysplasia (n=8)  IP with SCC (n=5)

P = 0.030
Table 1. Mutation rate in inverted papilloma, dysplasia and squamous cell carcinoma

| Gene   | All | IP  | Dysplasia | SCC | P    |
|--------|-----|-----|-----------|-----|------|
| TP53   | 79  | 70  | 75        | 91  | 0.467|
| GNAQ   | 41  | 50  | 50        | 27  | 0.483|
| PDGFRA | 17  | 10  | 36        |     | 0.088|
| EGFR   | 28  | 20  | 38        | 27  | 0.711|
| PIK3CA | 55  | 30  | 50        | 82  | 0.054|
| KRAS   | 52  | 10  | 75        | 73  | 0.004|
| APC    | 38  | 50  | 64        |     | 0.008|
| NRAS   | 21  | 25  | 36        |     | 0.113|
| STK11  | 14  |     | 36        |     | 0.022|
| KIT    | 3   |     | 9         |     | 0.428|
| MSH6   | 38  | 30  | 13        | 64  | 0.062|
| MET    | 10  | 30  |           |     | 0.041|
| FGFR2  | 17  | 20  | 13        | 18  | 0.911|
| SRC    | 28  | 20  | 50        | 18  | 0.248|

IP: inverted papilloma, SCC: squamous cell carcinoma
Table 2. Variants detected multiple times across all cases

| Gene     | Mutation | Position on chromosome | Mutation rate (%) |        |        |        |
|----------|----------|------------------------|-------------------|--------|--------|--------|
|          |          |                        |                   | All    | IP     | Dysplasia | SCC |
| TP53     | C>A      | 7570312                | 7                 | 10     | 10     | 26     | 18  |
|          | T>A      | 7577150                | 10                | 10     | 10     | 26     | 18  |
|          | G>T      | 7578511                | 10                | 10     | 10     | 26     | 18  |
|          | G>C      | 7579472                | 10                | 10     | 10     | 26     | 18  |
| GNAQ     | G>GAA    | 80343587               | 14                | 10     | 10     | 26     | 18  |
|          | G>GA     | 80343587               | 17                | 20     | 10     | 26     | 18  |
|          | GAA>G    | 80343587               | 7                 | 10     | 10     | 26     | 18  |
|          | GA>G     | 80343587               | 17                | 10     | 10     | 26     | 18  |
| PDGFRA   | A>G      | 55141055               | 7                 | 10     | 10     | 17     | 9   |
|          | C>T      | 55152040               | 7                 | 10     | 10     | 17     | 9   |
| EGFR     | C>CGGG   | 55249012               | 14                | 10     | 10     | 17     | 9   |
|          | AA>TT    | 55249013               | 10                | 25     | 10     | 17     | 9   |
|          | C>CGGGTTT| 55249012              | 7                 | 10     | 10     | 17     | 9   |
|          | G>A      | 55249063               | 7                 | 10     | 10     | 17     | 9   |
| PIK3CA   | C>T      | 178917627              | 7                 | 10     | 10     | 17     | 9   |
| KRAS     | G>A      | 25378661               | 14                | 10     | 10     | 26     | 18  |
|          | A>G      | 25362777               | 10                | 10     | 10     | 26     | 18  |
| APC      | C>T      | 112174550              | 7                 | 10     | 10     | 26     | 18  |
|          | G>A      | 112175642              | 10                | 10     | 10     | 26     | 18  |
|          | G>A      | 112175770              | 24                | 25     | 10     | 26     | 18  |
| STK11    | A>G      | 153247353              | 7                 | 10     | 10     | 26     | 18  |
| MSH6     | A>T      | 48030559               | 10                | 20     | 10     | 26     | 18  |
|          | AC>A     | 48030639               | 10                | 10     | 10     | 26     | 18  |
|          | A>AC     | 48030639               | 10                | 10     | 10     | 26     | 18  |
|          | T>A      | 48030692               | 17                | 10     | 10     | 26     | 18  |

IP: inverted papilloma, SCC: squamous cell carcinoma
Table 3. Mutation rate in the inverted papilloma tissue among patients with inverted papilloma alone, and those with dysplasia or squamous cell carcinoma

| Gene   | Mutation rate (%) | All | IP | Dysplasia/SCC | P    |
|--------|-------------------|-----|----|---------------|------|
| TP53   | 70                | 70  | 69 | 1.000         |
| GNAQ   | 57                | 50  | 62 | 0.897         |
| PDGFRA | 9                 | 10  | 8  | 1.000         |
| EGFR   | 22                | 20  | 23 | 1.000         |
| PIK3CA | 43                | 30  | 54 | 0.4719        |
| KRAS   | 48                | 10  | 77 | 0.005         |
| APC    | 17                | 31  | 0.169 |
| NRAS   | 17                | 31  | 0.169 |
| STK11  | 13                | 23  | 0.315 |
| KIT    | 4                 | 8   | 1.000 |
| MSH6   | 26                | 30  | 23 | 1.000         |
| MET    | 13                | 30  | 0.135 |
| FGFR2  | 13                | 20  | 8  | 0.807         |
| SRC    | 30                | 20  | 38 | 0.619         |

IP: inverted papilloma, SCC: squamous cell carcinoma